KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gross Profit (2019 - 2025)

Alnylam Pharmaceuticals' Gross Profit history spans 7 years, with the latest figure at $829.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 69.07% year-over-year to $829.3 million; the TTM value through Dec 2025 reached $2.5 billion, up 27.34%, while the annual FY2025 figure was $3.0 billion, 56.4% up from the prior year.
  • Gross Profit reached $829.3 million in Q4 2025 per ALNY's latest filing, down from $1.1 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.1 billion in Q3 2025 to a low of -$40.2 million in Q1 2025.
  • Average Gross Profit over 5 years is $380.0 million, with a median of $283.4 million recorded in 2022.
  • Peak YoY movement for Gross Profit: skyrocketed 194.58% in 2023, then crashed 109.14% in 2025.
  • A 5-year view of Gross Profit shows it stood at $224.9 million in 2021, then increased by 28.44% to $288.9 million in 2022, then increased by 27.31% to $367.7 million in 2023, then skyrocketed by 33.39% to $490.5 million in 2024, then soared by 69.07% to $829.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Gross Profit are $829.3 million (Q4 2025), $1.1 billion (Q3 2025), and $631.7 million (Q2 2025).